HDVY & HGSI**Compare & Contrast…
This is Trading very steadly up today, might want to read!
First, please understand that the thoughts within this post are not to be a putdown on HGSI. HGSI is a solid company with a bundles of legit products. What I am trying to do is to show how HDVY is still significantly undervalued at today’s price per share (pps) versus where HGSI is currently trading by comparing and contrasting a few different fundamental variables given both companies are somewhat similar in nature in what they bring to the market. I will do my best to make as simple as possible.
Market Cap = Current Share Price x Outstanding Shares (OS)
HGSI Current Share Price = $27.95
HDVY Current Share Price = .20
HGSI OS = 135,548,419 Shares
HDVY OS = 181,491,025 Shares
HGSI Market Cap = .27.95 x 135,548,419 Shares = $3,711,315,712 (yes that is billion with a B)
HDVY Market Cap = .20 x 42,715,110 Shares = $36,336,549
HGSI Market Cap of $3,711,315,712 = HDVY Market Cap of $36,336,549
$3,711,315,712 ÷ $36,336,549= HDVY Undervaluation to HGSI by Market Cap Comparison
102.13 = HDVY Undervaluation to HGSI by Market Cap Comparison
This means that HDVY is ”potentially” 102.13 times undervalued in price in comparison to the $27.95 share price of HGSI which it’s trading at today. This is saying that HDVY should at the very least be somewhere much higher than the .20 per share price that it’s at now.
In Summary
** HGSI and HDVY both trades on the OTCBB.
** HGSI is at $27.95 per share and HDVY is at .20 per share.
** The Market Cap for HGSI is $3,711,315,712
** The Market Cap for HDVY is $36,336,549
** The HDVY Market Cap is 102.13 times lower than HGSI’s Market Cap with HDVY having a much better technology, similar share structure, higher Revenue potential, and much more. This Market Cap disparity between HDVY and HGSI could justify HDVY trading in the area indicated below…
102.13 x .20 HDVY share price = $20.43 per share “Disparity Valuation”
As a guess, as details are announced about their contracts, $20.43 per share should prove to be very attainable.
IMPORTANTLY and to further add…
Major Partnerships w/ Pfizer (NYSE), Abbott (NYSE), Quest Diagnostics (NYSE), CLRT (NASD), IART (NASD), BRKR (NASD) . These FORTUNE 500 companies have to pay royalty fees forever to these HDVY since HDVY licenses their SVM-RFE Technology to them and this company is not even $1.00. VRLMQ went from .06 to almost $20/share on the approval of the OVA (Ovarian Test) using the technology licensed to them by HDVY. Demonstrates how undervalued HDVY is at .38.
HDC’s License Partners (From 10/19/09 PR)
* HDC’s key license partners to date include Abbott Laboratories (NYSE: ABT - News), Quest Diagnostics (NYSE: DGX - News), Clarient Inc. (Nasdaq: CLRT - News) and Pfizer Inc. (NYSE: PFE - News).
* HDC recently entered into royalty-bearing licenses for its new urine-based prostate cancer test with Quest Diagnostics Incorporated and Abbott Laboratories for development and commercialization. These licenses are solely for the use of HDC’s prostate cancer biomarkers in urine.
* HDC also entered into royalty-bearing licenses for its tissue biopsy-based prostate cancer test with Abbott Laboratories and Clarient Inc. for development and commercialization. This license is solely for the use of HDC’s prostate cancer biomarkers in tissue biopsy specimens.
* HDC has also partnered with Pfizer Inc. for use of HDC’s SVM and SVM-RFE pattern recognition technology in Pfizer’s global research and development.
HDC has also entered into a license with Smart Personalized Medicine, LLC (“SPM”), a privately-held company, founded by Dr. Richard Caruso, Chairman and founder of Integra Life Sciences (NasdaqGS: IART - News) to develop a superior breast cancer prognostic test using HDC’s SVM technology in cooperation with MD Anderson Cancer Center. HDC has a fifteen percent equity position in SPM and HDC will receive royalties from this new breast cancer prognostic test.
HDC has entered into a development and license agreement with DCL Medical Laboratories, LLC, for the collaborative development and commercialization of SVM-based computer assisted diagnostic tests for the independent detection of ovarian, cervical and endometrial cancers.
* HDC’s Patents Cover Non-Medical Applications
There are a large number of non-medical applications protected by HDC’s patents, including but not limited to, fraud detection, investment and commodities price predictions, bankruptcy prediction, image and object analysis, face recognition, text and document classification, speech recognition, personalized consumer purchasing patterns, decryption, vehicle control and monitoring, weather forecasting and database marketing.
Total Number of Patents Pending and Issued
With the issuance of the new patents described above, HDC now holds exclusive rights to a total of 37 issued U.S. and foreign patents. There will be 41 when the 4 new ones (subjects of the Notices of Allowance) issue in the next few months. HDC has a total of 71 patents pending and issued. Importantly, the first expiration of any of the HDC patents is May 2019 and new patents are currently being filed which when granted will have an additional 20 years of protection for the Company.
HDC’s Successful Prosecution of Patent Infringement Cases
In addition to the Vermillion patent infringement case described above, HDC successfully prosecuted a patent infringement lawsuit against Equbits LLC, which resulted in a permanent injunction against Equbits, LLC.
“HDC is determined to continue to grow and protect its valuable intellectual property portfolio. The Equbits judgment and Vermillion settlement and limited license strengthens our licensing posture in the marketplace and sets the appropriate tone for our future enforcement efforts,” stated Stephen D. Barnhill, M.D., HDC’s Chairman and CEO.
“HDC remains firmly committed to successfully monetizing our valuable intellectual property through additional licensing, close collaboration, development and commercialization with our business partners and we will also continue to protect our patent portfolio through robust enforcement action when strategically appropriate," said Dr. Barnhill.
HDC’s patent strategy includes a significant after-claiming component with multiple CIP’s and Continuations already in place.
Special thanks to $heff, and Stervc for the dd and borrowed format.
11/13/09 HDVY OS 181,491,02
This is IMO and I do hold this stock.
please sticky, lots of info and research went into this. I ruined my keyboard.
AI
